Tony Tiganis
Overview
Explore the profile of Tony Tiganis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
103
Citations
3856
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bennett A, Tiganis T
Annu Rev Physiol
. 2024 Nov;
87(1):301-324.
PMID: 39531392
The increased prevalence of chronic metabolic disorders, including obesity and type 2 diabetes and their associated comorbidities, are among the world's greatest health and economic challenges. Metabolic homeostasis involves a...
2.
Fernandez-Tussy P, Cardelo M, Zhang H, Sun J, Price N, Boutagy N, et al.
JCI Insight
. 2024 Aug;
9(19).
PMID: 39190492
The complexity of the mechanisms underlying metabolic dysfunction-associated steatotic liver disease (MASLD) progression remains a significant challenge for the development of effective therapeutics. miRNAs have shown great promise as regulators...
3.
Greatorex S, Kaur S, Xirouchaki C, Goh P, Wiede F, Genders A, et al.
J Clin Invest
. 2023 Dec;
134(3).
PMID: 38060313
Nonalcoholic fatty liver disease (NAFLD) is prevalent in the majority of individuals with obesity, but in a subset of these individuals, it progresses to nonalcoholic steatohepatitis (0NASH) and fibrosis. The...
4.
Xi Y, Liu S, Bettaieb A, Matsuo K, Matsuo I, Hosein E, et al.
Diabetologia
. 2023 Oct;
67(1):215.
PMID: 37861718
No abstract available.
5.
Wiede F, Shields B, Kyparissoudis S, van Vliet C, Galic S, Tremblay M, et al.
J Clin Invest
. 2023 Oct;
133(20).
PMID: 37843283
No abstract available.
6.
Qiu B, Lawan A, Xirouchaki C, Yi J, Robert M, Zhang L, et al.
Nat Commun
. 2023 Sep;
14(1):5405.
PMID: 37669951
Nonalcoholic steatohepatitis (NASH) is triggered by hepatocyte death through activation of caspase 6, as a result of decreased adenosine monophosphate (AMP)-activated protein kinase-alpha (AMPKα) activity. Increased hepatocellular death promotes inflammation...
7.
Qiu B, Lawan A, Xirouchaki C, Yi J, Robert M, Zhang L, et al.
bioRxiv
. 2023 Jul;
PMID: 37502892
Nonalcoholic steatohepatitis (NASH) is triggered by hepatocyte death through activation of caspase 6, as a result of decreased adenosine monophosphate (AMP)-activated protein kinase-alpha (AMPKα) activity. Increased hepatocellular death promotes inflammation...
8.
Liang S, Tran E, Du X, Dong J, Sudholz H, Chen H, et al.
Nat Commun
. 2023 Jul;
14(1):4524.
PMID: 37500611
The inhibition of protein tyrosine phosphatases 1B (PTP1B) and N2 (PTPN2) has emerged as an exciting approach for bolstering T cell anti-tumor immunity. ABBV-CLS-484 is a PTP1B/PTPN2 inhibitor in clinical...
9.
Liang S, Tran E, Du X, Dong J, Sudholz H, Chen H, et al.
bioRxiv
. 2023 Jul;
PMID: 37397992
The inhibition of protein tyrosine phosphatases (PTPs), such as PTP1B and PTPN2 that function as intracellular checkpoints, has emerged as an exciting new approach for bolstering T cell anti-tumor immunity...
10.
Morris R, Keating N, Tan C, Chen H, Laktyushin A, Saiyed T, et al.
Commun Biol
. 2023 Jun;
6(1):641.
PMID: 37316570
Protein Tyrosine Phosphatase 1B (PTP1B) is the prototypical protein tyrosine phosphatase and plays an essential role in the regulation of several kinase-driven signalling pathways. PTP1B displays a preference for bisphosphorylated...